Bionano Genomics (NASDAQ:BNGO – Get Free Report) and Codexis (NASDAQ:CDXS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.
Institutional & Insider Ownership
11.3% of Bionano Genomics shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by insiders. Comparatively, 3.5% of Codexis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Bionano Genomics and Codexis”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bionano Genomics | $28.51 million | 0.51 | -$26.40 million | ($1.97) | -0.53 |
| Codexis | $70.39 million | 1.49 | -$43.97 million | ($0.34) | -2.82 |
Bionano Genomics has higher earnings, but lower revenue than Codexis. Codexis is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for Bionano Genomics and Codexis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bionano Genomics | 1 | 0 | 1 | 0 | 2.00 |
| Codexis | 1 | 1 | 2 | 0 | 2.25 |
Bionano Genomics presently has a consensus target price of $6.00, suggesting a potential upside of 476.92%. Codexis has a consensus target price of $6.50, suggesting a potential upside of 578.43%. Given Codexis’ stronger consensus rating and higher possible upside, analysts clearly believe Codexis is more favorable than Bionano Genomics.
Risk and Volatility
Bionano Genomics has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, Codexis has a beta of 2.38, meaning that its share price is 138% more volatile than the S&P 500.
Profitability
This table compares Bionano Genomics and Codexis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bionano Genomics | -96.87% | -85.00% | -51.86% |
| Codexis | -39.55% | -74.36% | -23.58% |
Summary
Codexis beats Bionano Genomics on 12 of the 14 factors compared between the two stocks.
About Bionano Genomics
Bionano Genomics, Inc. is a life sciences company that develops genomic analysis tools designed to help researchers and clinicians detect large-scale structural variations in DNA. Its technology is intended to complement or extend conventional sequencing and cytogenetic methods by providing information about changes in genome structure, including deletions, duplications, inversions and translocations. The company’s principal platform is the Saphyr system, an optical genome mapping solution that analyzes ultra-high-molecular-weight DNA.
About Codexis
Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
